Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Biocon and FUJIFILM Pharma Launch Insulin Biosimilar in Japan
July 18, 2016
India's largest biopharma company Biocon (Bangalore, India) and partner FUJIFILM Pharma (Tokyo, Japan) launched the biosimilar Insulin Glargine in Japan last week.
The Insulin Glargine BS Injection Kit is "a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine". Biocon and FUJIFILM Pharma aim to capture a significant share of the Japanese Glargine market of US$ 144 million, the second largest market outside of North America & Europe. According to the International Diabetes Federation, there were 7.2 million people with diabetes in Japan in 2015.
Recent Videos
Related Content
